| Literature DB >> 20658357 |
C R M Lammens1, E M A Bleiker, N K Aaronson, A Wagner, R H Sijmons, M G E M Ausems, A H J T Vriends, M W G Ruijs, T A M van Os, L Spruijt, E B Gómez García, A Cats, T Nagtegaal, S Verhoef.
Abstract
Li Fraumeni Syndrome (LFS) is a hereditary cancer syndrome characterized by a high risk of developing various types of cancer from birth through late adulthood. Clinical benefits of surveillance for LFS are limited. The aim of this study is to investigate which advice for regular surveillance, if any, is given to high risk LFS individuals, adherence to that advice, and any psychological gain or burden derived from surveillance. Fifty-five high risk individuals (proven carriers and those at 50% risk) from families with a p53 germline mutation were invited to participate, of whom 82% completed a self-report questionnaire assessing advice for regular surveillance, compliance, perceived benefits and barriers of screening and LFS-related distress (IES) and worries (CWS). In total, 71% of the high risk family members received advice to undergo regular surveillance for LFS. The majority (78%) reported adherence with the recommended advice. All high risk women aged 25 or older reported having been advised to undergo annual breast cancer surveillance (n = 11), of whom 64% (n = 7) in specific received advice to undergo a mammography. Seventy-eight percent of respondents indicated having received tailored surveillance advice based on family cancer history. The large majority of respondents believed in the value of surveillance to detect tumors at an early stage (90%) and reported that it gave them a sense of control (84%) and security (70%). Despite its limited clinical benefits, the majority of high risk LFS family are advised to undergo, and are adherent to, and report psychological benefit from, regular surveillance programs.Entities:
Mesh:
Year: 2010 PMID: 20658357 PMCID: PMC2980620 DOI: 10.1007/s10689-010-9368-z
Source DB: PubMed Journal: Fam Cancer ISSN: 1389-9600 Impact factor: 2.375
Demographics study sample
| Characteristics | Total ( | Compliers ( | Non-compliers ( | No advice ( |
|---|---|---|---|---|
| Age (mean ± SD (range)) | 40.6 ± 15.2 (17–75) | 44.8 ± 14.4 | 39.7 ± 13.7 | 32.2 ± 15.1 |
| Gender (female) | 19 (42%) | 10 (40%) | 4 (57%) | 5 (39%) |
| Marital status | ||||
| Married/living together | 31 (69%) | 21 (84%) | 6 (86%) | 4 (31%) |
| Single | 14 (31%) | 4 (16%) | 1 (14%) | 9 (69%) |
| Education level | ||||
| Low | 14 (31%) | 9 (36%) | 2 (28%) | 3 (23%) |
| Moderate | 18 (40%) | 9 (36%) | 3 (43%) | 6 (46%) |
| High | 13 (29%) | 7 (28%) | 2 (29%) | 4 (31%) |
| Children (yes) | 25 (56%) | 17 (68%) | 3 (43%) | 5 (39%) |
| Actual risk | ||||
| Carrier | 27 (60%) | 20 (80%) | 3 (43%) | 4 (31%) |
| 50% at risk | 18 (40%) | 5 (20%) | 4 (57%) | 9 (69%) |
| Cancer history (yes) | 10 (22%) | 9 (36%) | 0 (0%) | 1 (8%) |
Fig. 1Flowchart advice and adherence to regular surveillance for LFS
Screening recommendations received by high risk LFS family members
| Recommended screening | Carriers | 50% At risk | Total |
|---|---|---|---|
|
| ( | ( | ( |
| Annual medical consultation* | 18 (78%) | 5 (56%) | 23 (72%) |
| Tailored screeninga | 19 (83%) | 6 (67%) | 25 (78%) |
|
| ( | ( | ( |
| Annual breast MRIc | 3 (43%) | 3 (43%) | 6 (43%) |
| Annual mammographyd | 5 (71%) | 2 (29%) | 7 (50%) |
* Medical consultation includes a anamnesis and/or physical examination by a physician
aTailored screening refers to organ-targeted surveillance based on family history, here including: colonoscopies (n = 9), endoscopic ultrasound pancreas (n = 4), MRI pancreas (n = 4), examination by a dermatologist (n = 14), ultrasound of kidneys (n = 10), urine analysis (n = 5), total blood count (n = 5)
bOf the 14 women, 12 were aged ≥ 25 years or older (7 carriers and 5 at 50% risk), 2 were aged < 25 years (both at 50% risk)
cAll women who were advised to undergo a regular breast MRI were age 25 years or older
dAll women who were advised to undergo a regular mammography were age 25 years or older
Perceived benefits & barriers of screening for LFS (n = 31)
| Total ( | Adherent ( | Not (fully) adherent ( | |
|---|---|---|---|
| Benefits of screening | |||
| Reduces the chance of cancer being detected in an advanced stage | 90% | 96%b | 67%b |
| Reduces my fear of cancer | 61% | 72%a | 17%a |
| Provides me with a feeling of control | 84% | 92%a | 50%a |
| Gives me a sense of security | 77% | 84% | 50% |
| Is a good way to detect cancer early | 90% | 92% | 83% |
| Total scale score benefits (mean ± SD) | 20.6 ± 3.7 | 21.3 ± 3.4a | 17.7 ± 3.6a |
| Barriers of screening | |||
| Can have a negative effect on my home mortgage and/or life and health insurance | 42% | 44% | 33% |
| Can cause unnecessary worry | 36% | 28% | 67% |
| Causes inconvenience in my life | 13% | 8% | 33% |
| Screening is not important, if I am diagnosed with cancer it will be too late | 3% | 4% | 0% |
| Is painful | 0% | 0% | 0% |
| Is uncomfortable/embarrassing | 10% | 8% | 17% |
| Total scale score barriers (mean ± SD) | 12.8 ± 3.2 | 12.4 ± 2.8 | 14.0 ± 4.6 |
* 1 case missing in analysis
aSignificant difference p ≤ .05
bBorderline significant p ≤ .10